{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+capsules+twice+a+day&page=3", "query": { "intervention": "Placebo capsules twice a day", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 849, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+capsules+twice+a+day&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+capsules+twice+a+day&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T17:08:57.000Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03698513", "title": "A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "BMS-986177", "type": "DRUG" }, { "name": "Placebo (for BMS-986177)", "type": "OTHER" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 113, "start_date": "2018-10-04", "completion_date": "2019-02-19", "has_results": false, "last_update_posted_date": "2021-09-29", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03698513" }, { "nct_id": "NCT01075048", "title": "ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Tivantinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 131, "start_date": "2010-01-26", "completion_date": "2015-02-20", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 24, "location_summary": "Beverly Hills, California • Encinitas, California • Fountain Valley, California + 21 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01075048" }, { "nct_id": "NCT02449018", "title": "A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease, COPD" ], "interventions": [ { "name": "QBW251", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 92, "start_date": "2015-04-30", "completion_date": "2017-01-23", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Fullerton, California • Waterbury, Connecticut + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Waterbury", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02449018" }, { "nct_id": "NCT06714942", "title": "Efficacy and Safety of a Proprietary Blend of Ashwagandha Root Extract (Aqueous) in Adult Men and Women With High Stress and Anxiety: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stress", "Anxiety" ], "interventions": [ { "name": "Proprietary Blend of Ashwagandha", "type": "DIETARY_SUPPLEMENT" }, { "name": "KSM-66 Ashwagandha root extract", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "SF Research Institute, Inc.", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 51, "start_date": "2024-10-25", "completion_date": "2025-01-21", "has_results": false, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06714942" }, { "nct_id": "NCT01271790", "title": "A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Tegobuvir (GS-9190)", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "Pegasys®", "type": "BIOLOGICAL" }, { "name": "Copegus®", "type": "DRUG" }, { "name": "Tegobuvir placebo", "type": "DRUG" }, { "name": "GS-9451 placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 245, "start_date": "2010-10", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 85, "location_summary": "Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01271790" }, { "nct_id": "NCT00218023", "title": "Medications for Stopping Cocaine Dependence and Preventing Relapse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cocaine Abuse", "Cocaine-Related Disorders" ], "interventions": [ { "name": "Modafinil", "type": "DRUG" }, { "name": "Levodopa/Carbidopa", "type": "DRUG" }, { "name": "Naltrexone HCl", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Motivational Interviewing (MI)", "type": "BEHAVIORAL" }, { "name": "Contingency management (CM)", "type": "BEHAVIORAL" }, { "name": "Cognitive-Behavioral Therapy (CBT)", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 101, "start_date": "2006-03", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2017-06-09", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00218023" }, { "nct_id": "NCT03070470", "title": "CiPA Phase 1 ECG Biomarker Validation Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-induced QT Prolongation", "Pharmacokinetics", "Pharmacodynamics" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Lopinavir / Ritonavir", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dofetilide and Diltiazem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Food and Drug Administration (FDA)", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 60, "start_date": "2017-03-14", "completion_date": "2017-06-26", "has_results": true, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 1, "location_summary": "West Bend, Wisconsin", "locations": [ { "city": "West Bend", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03070470" }, { "nct_id": "NCT00087256", "title": "Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2004-07", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2013-01-07", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087256" }, { "nct_id": "NCT00797953", "title": "Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Angina Pectoris" ], "interventions": [ { "name": "T89", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tasly Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 124, "start_date": "2007-02", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-12-12", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 15, "location_summary": "Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Lauderdale Lakes", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00797953" }, { "nct_id": "NCT04490460", "title": "Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Abnormal Glucose Tolerance" ], "interventions": [ { "name": "WBF-0031", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Eden Miller", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2020-06-01", "completion_date": "2021-02-28", "has_results": false, "last_update_posted_date": "2020-07-29", "last_synced_at": "2026-10-09T17:08:57.000Z", "location_count": 1, "location_summary": "Bend, Oregon", "locations": [ { "city": "Bend", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04490460" } ] }